Show
Sort by
-
Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
-
Inference failure with synthetic arms : empirical application to phase III oncology trials
-
Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+oropharyngeal cancer that progressed with prior anti-PD-1 therapy
-
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors : results from phase I dose exploration5
-
Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer
-
First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
-
Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
-
Current care for patients on oral anticancer therapy through a different lens : assessment from a patient and healthcare professional perspective
-
Mentoring programs for specialised and advanced practice nurses : a systematic review
-
Dynamics and processes influencing role integration of advanced practice nurses and nurse navigators in oncology teams